Lineage Cell Therapeutics, Inc. LCTX
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Lineage Cell Therapeutics, Inc. (LCTX) is a healthcare company listed in the US with a market value of about $231M. In the twelve months to September 30, 2026 it had revenue of $11M and net income of $2M, a net margin of 16.2%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 51% a year, a 5-year average ROIC of -39%.
About Lineage Cell Therapeutics
Lineage Cell Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $5M in 2014 to $15M in 2025, growth of about 9.7% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 36% over three years (dilution for shareholders). It spends 122% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11M | $15M | $9M | $9M | $15M | $4M | $2M | $4M | $5M | $3M | — |
| Net income | $2M | -$64M | -$19M | -$21M | -$26M | -$43M | -$21M | -$12M | -$46M | -$20M | $34M |
| Free cash flow | -$26M | -$19M | -$24M | -$29M | $646000 | -$24M | -$20M | -$32M | -$31M | -$32M | -$45M |
| EPS (diluted) | $-0.09 | $-0.28 | $-0.09 | $-0.12 | $-0.15 | $-0.26 | $-0.14 | $-0.08 | $-0.36 | $-170.00 | $340.00 |
| Net margin | 16.2% | -436.5% | -195.9% | -240.2% | -178.7% | -991.0% | -1130.8% | -333.1% | -922.0% | -577.7% | — |
| ROIC | — | -72.1% | -26.6% | -34.4% | -23.1% | -40.9% | -25.9% | -21.0% | -34.5% | -18.9% | -39.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $5.50, 501% above the current price; targets range from $3.00 to $9.00; the consensus rating is “Strong buy”; expected EPS is $-0.09 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Lineage Cell Therapeutics pay a dividend?
Not currently.
Is Lineage Cell Therapeutics a good stock to buy?
We do not give buy or sell advice. Lineage Cell Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.